AMICUS THERAPEUTICS, INC.
At today's price, AMICUS THERAPEUTICS, INC. (FOLD) is priced for today's economics sustained for ~17.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
The single fact that overrides everything else: Amicus has agreed to be acquired by BioMarin for $14.50 a share in all cash, about $4.8 billion, with the deal expected to close in the second quarter of 2026. The stock trades right at that price, so this is now a merger situation, not a standalone-valuation story. That is why every fundamental valuation method lands far below the price. The cash takeout value, a 33% premium to the undisturbed price, is what the market is paying for, and the stat
Is FOLD overvalued? See what's priced in →
286 institutional managers reported holding FOLD in 13F filings for the quarter ended 2026-03-31. 44 opened new positions that quarter. Held by BlackRock, Vanguard Group, UBS, among others.
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
FOLD's share count grew 15.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at FOLD over the trailing three years. Absence is a fact about the company, not a signal. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
FOLD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-03-02 | -3.9% | -6.5% |
| 2023-05-11 | -4.2% | +11.9% |
| 2023-08-09 | +9.2% | -20.6% |
| 2023-11-09 | -14.9% | +33.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.